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0022-2836 © 2007 Elsevier Ltd. Open acceThe complement (C) system is a potent innate immune defence system
against parasites. We have recently characterised and expressed OmCI, a
16 kDa protein derived from the soft tick Ornithodoros moubata that
specifically binds C5, thereby preventing C activation. The structure of
recombinant OmCI determined at 1.9 Å resolution confirms a lipocalin fold
and reveals that the protein binds a fatty acid derivative that we have
identified by mass spectrometry as ricinoleic acid. We propose that OmCI
could sequester one of the fatty acid-derived inflammatory modulators
from the host plasma, thereby interfering with the host inflammatory
response to the tick bite. Mapping of sequence differences between OmCI
and other tick lipocalins with different functions, combined with bio-
chemical investigations of OmCI activity, supports the hypothesis that
OmCI acts by preventing interaction with the C5 convertase, rather than by
blocking the C5a cleavage site.© 2007 Elsevier Ltd. Open access under CC BY license. *Corresponding authors Keywords: OmCI; tick; complement C5; complement inhibitor; lipocalinIntroduction
Complement (C) is a potent, frontline, innate
immune defence system that comprises approxi-
mately 30 fluid-phase and membrane-associated
proteins.1 C activation results in the release of the
acute inflammatory peptide mediators C3a and
C5a2 by the C3 and C5 convertases, and formation
of the terminal membrane attack complex (MAC,
comprising C5b–C9) which can lyse cells directly, or
trigger a variety of cellular activation events.3
Activated complement can inflict damage to the
body's own tissues and has been implicated in
numerous inflammatory disorders.4 Activation
occurs via a tightly regulated proteolytic cascade,
which is dependent on conformational changes
induced by multi-protein complexes and by the
cleavage events themselves. Additional regulation is
achieved by both the short half-lives of activated C
components and (in humans) more than 14 serum
and cell-surface C regulatory proteins. Although the
functional roles of C proteins are broadly under-
stood, relatively few C component structures haveding authors:
c.uk
ss under CC BY license. been described, and even fewer atomic interactions
elucidated in detail.5,6
Parasites that fail to control C activation may be
damaged or killed by the host's inflammatory
response, and by elaboration of the immune
response orchestrated by complement. Most para-
sites express specific inhibitory proteins, or produce
physical barriers and/or sequester host regulatory
molecules to counteract C activity.7–10 The ticks,
obligate ectoparasites (Acari, Parasitiformes), coun-
teract harmful effects of C by secreting inhibitors
into their feeding site.11,12 We have recently char-
acterised OmCI, a 16 kDa protein derived from the
soft-tick Ornithodoros moubata that specifically binds
C component C5 in solution, prevents cleavage of
C5a from C5, and thus inhibits formation of the
MAC.13 OmCI belongs to a family of about 20 tick
lipocalins that sequester mediators of inflammation
from the host plasma.14 On the basis of sequence
homology, a subfamily of tick lipocalins comprising
the tick salivary gland proteins 1–3 (TSGP1–TSGP3)
from the soft tick Ornithodoros savignyi, and mouba-
tin from O. moubata, are likely to share the same
molecular architecture as OmCI,15 but no structure
is available for any member of this subfamily.
OmCI is the first parasite molecule described that
specifically targets C5, a member of the C3/C4/C5
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terminal C multiprotein complexes. Only one other
natural C5 inhibitor is known to date, the Staphylo-
coccus aureus protein SSL7.16 Mature C5 comprises
an α and β chain (115 kDa and 75 kDa, respectively)
associated via a disulphide bond. Figure 4(c) illus-
trates the two-chain structure of the molecule. In a
step crucial to terminal complement pathway ac-
tivation, C5 is cleaved by the trimeric alternative
and classical pathway C5 convertases (C3bBbC3b
and C4bC2bC3b, respectively) at the peptide bond
between residues R751 and L752. This cleavage
splits off the N-terminal domain of the C5α chain,
which is called the C5 anaphylotoxin or C5a (orange
in Figure 4(c)) from the rest of the molecule, a much
larger fragment called C5b. Following cleavage, C5b
transiently gains the ability to interact with C6, and
the C5bC6 complex is the hub for sequential
assembly of C7, C8 and C9 that form the MAC.
Structures for theC3a, C3d andC4d fragments17–19
have been known for some time; the structures
of whole C320 and its fragments C3c20 and C3b21–23
were determined more recently. Details of the
interactions between C3/C4/C5 family members
remain undefined, and only a few small, indepen-
dently folding domains within C5 have been
described. These include NMR solution structures
for the C5a fragment (8 kDa),24,25 and for the 17 kDa
C-terminal C345C domain of the α chain of C5b
(cyan in Figure 4(c)).26 The C345C domain of C5
appears to be multifunctional, with roles in both C5
cleavage and MAC assembly.27,28 It interacts with
the C5 convertase;26 the C5 C345C residues that are
critical for the interaction with the C5 convertase
cluster on a mobile hydrophobic loop that protrudes
from the domain.26,29
C5 inhibition with a humanized anti-C5 antibody
forms the basis of a successful therapy against noc-
turnal paroxysmal hemoglobulinuria.30,31. Anti-C5
antibodies are also being developed to fight comple-
ment-mediated tissue damage in a range of clinical
contexts, such as myocardial infarction,32 cardiac
surgery,33 and systemic lupus erythematosus.34
OmCI prevents cleavage of C5 by both the classical
and alternative C5 convertases13; its half life in vivo in
mice is about 30 h, due to its high-affinity binding to
C5 with a slow dissociation rate;35 no detailed
knowledge is available about the exact site(s) of
interaction between C5 and its convertases but, since
OmCI inhibits human, mouse35 and guinea pig C,
the inhibitor must bind to an element or elements of
C5 that are conserved between species. We present
here the atomic structure of OmCI, determined by X-
ray diffraction at 1.9 Å resolution; the OmCI
construct studied here is the double mutant N78Q/
N102Q that allowed expression in Pichia methanolica
(see Materials and Methods) and is termed pOmCI.
We used biochemical and structure-based analyses
to formulate hypotheses about the molecular basis of
OmCI activity. This work is the first step toward the
elucidation of OmCI C inhibition, and contributes to
current investigations of the therapeutic potential of
the inhibitor.Results
Atomic structure for OmCI
OmCI displays a standard lipocalin fold (Figure
1), with a central eight-stranded antiparallel β
barrel, flanked by the C-terminal helix (labelled 3
in Figure 1). As seen in hard-tick lipocalins,14,36 this
helix is pinned to the barrel by a disulphide bond
(C118–C147, Figure 1(a)), while a second disulphide
bond links the terminal cysteine residue to the loop
between the first two strands (C56–C168, Figure
1(a)). The N-terminal portion, containing amixed α/
310 helix (labelled ‘2’ in Figure 1 and αA/ηA in
Figure 2(a)), closes the bottom of the β-barrel; the
αA/ηA helix is interrupted in the middle at residue
F36, which is involved in ligand binding (see below).
The main novel structural feature of OmCI is the
extra disulphide bond C24–C146 (SS bond number 1
in Figure 2(a)), which ties the N-terminal portion to
helix α3; this disulphide bond was predicted by
Mans et al. for OmCI sequence homologues.15 Thus,
the mature protein (starting at residue 18) is tethered
by disulphide bonds close to both the N and the C
terminus, a feature that may confer extra resistance
to proteases. No ordered electron density is visible
in the crystal for the first four residues at the N
terminus (sequence DSES): the traceable electron
density starts at D23, the residue immediately
preceding the first cysteine.
The pocket and the lipid
The pocket at the centre of the pOmCI β-barrel in
the crystal contains a ligand, a model for which was
initially built in the residual electron density as a C18
fatty acid (see Figure 3(a) for the electron density
used for the first model building). GC-MS after
extraction from a pOmCI sample and esterification
(see Materials and Methods) identified the methyl
ester of ricinoleic acid ((R)-12-hydroxy-cis-9-octade-
cenoic acid), C18H34O3, as the major product (47%);
minor components were identified as tetraethylene-
glycol diethylether (21%), palmitic acid methyl ester
(21%), and stearic acid methyl ester (11%). The
presence of palmitic acid and stearic acid methyl
esters was confirmed by GC-MS analysis of pure
samples of the same esters. Tetraethyleneglycol
diethylether is commonly observed when plastics
have been used to store samples. The methyl ester of
ricinoleic acid displayed characteristic even-num-
bered fragment ions at m/z 294 (M+-H2O), m/z 198,
m/z 166,m/z 124, andm/z 74, facilitating identifica-
tion. Moreover, the methyl ester of the protein-
associated fatty acid and the methyl ester of
authentic ricinoleic acid eluted at identical retention
times and showed coincident mass spectra.
The most likely origin of the ricinoleic acid bound
to pOmCI in the crystals is the medium used for
expression of the recombinant protein,13 as a sample
of native OmCI purified from tick salivary gland
extract did not show any ricinoleic acid, nor signifi-
Figure 1. (a) Cartoon representations of the OmCI molecule from the P212121-A crystal form. Colour: blue to red, from
N terminus to C terminus. The cysteine side-chains and the ricinoleic acid ligand are shown in stick representation, with C
atoms coloured orange, O red and S green. The strands and helices are labelled following the tick lipocalin
nomenclature.36 (b) OmCI molecular surface coloured by electrostatic potential, in the same orientations as in (a).
Contours: −2 kT/e, red; +2 kT/e, blue. The pictures were produced with the PyMol [http://www.pymol.sourceforge.
net/]. The electrostatic potential was computed with the program APBS42, run within PyMol, with the following
parameters: εprotein=2.0; εsolvent=78.0; ionic strength, 150mMNaCl. In (a) and (b), views 1 and 2 are rotated by 90° around
the horizontal axis.
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GC-MS (data not shown).
In the pOmCI crystals, the carboxylic moiety of
ricinoleic acid faces the solvent at the opening of the
β-barrel, where it forms a hydrogen bond with T85,
and interacts with the positively charged head of
R54. The rest of the molecule fits snugly into the
L-shaped pocket, with a kink at position 12, where
the hydroxyl group is hydrogen bonded to H119
and D121 (see Figure 3(b)). The C9=C10 double bond
stacks against the guanidinium head of R107. These
interactions, together with other hydrophobic pro-
tein–ligand contacts with the side-chains of residues
F36, L57, G59, V72, M74, F76, W87, F89 and W133,
account for a contact area of about 280 Å2 (as
computed with the program CCP4-areaimol37).Structural and sequence homologues
A DALI search38 using the OmCI coordinates on
the Protein Data Bank as of April 2006 returns the
tick histamine-binding protein HBP (PDB ID 1QFT,
rmsd 1.2 Å over 103 Cα atoms ; this is the model that
was used to determine the OmCI structure by
molecular replacement) and the Escherichia coli
putative phospholipid-binding lipocalin BLC (PDB
ID 1QWD, rmsd 1.4 Å over 77 Cα atoms), plus a
number of other lipocalins, as the closest OmCI
structural homologues. However, sequence similar-
ity and especially conservation of the cysteine
residues, puts proteins of unknown structure closer
to OmCI: the tick salivary gland proteins 1, 2 and 3
(TSGP 1–3) from the soft tick Ornithodoros savignyi,39
Figure 2. (a) The annotated sequences of OmCI (Uniprot Entry Q5YD59) and its closest soft tick protein homologues,
TSGP2 and TSGP3 from O. savignyi (UniProt Entries Q8I9U1 and Q8I9U0) and moubatin from O. moubata (UniProt Entry
Q04669). White font on green background, identical residues; white font on orange background, Risler similarity score 55
greater than 0.7. The secondary structure of OmCI is displayed above the sequences: beta sheets are symbolised by
arrows, and helices by wiggly lines; below each cysteine residue, the disulphide bridge the cysteine residue belongs to
is labelled in green (disulphide bridge1, Cys24–Cys146; disulphide bridge 2, Cys56–Cys168; disulphide bridge 3,
Cys118–Cys147); starred residues are involved in contact with the ligand. The N-terminal residue of mature OmCI is D19.
The Figure was prepared with the computer program ESPript.56 (b) The cartoon and surface representation of the OmCI
residues that show conservation (green) or similarity (orange) in the family of proteins whose sequences are given in (a).
Protein orientations are the same as in Figure 1. For reference purposes, the N terminus and a few of the loops are labelled.
787Structure of the Tick Complement Inhibitor OmCIwith sequence identities in the range 38.5–58%; and
moubatin from the soft tick O. moubata (sequence
identity 49%).40 Most of the sequence differences
between OmCI and these sequence homologues
localise to loops between the central strands of the
barrel (see Figure 2(b)). More distant relatives of
OmCI that still preserve all the cysteine residues are
O. savignyi TSGP4 (22% sequence identity) and Arg-
r-1, an allergen from Argas reflexus (24% sequenceidentity).41 (An up-to-date list of all the family
members is available as Supplementary Data).
Analysis of the surface properties of OmCI
structure
The electrostatic potential around the OmCI mole-
cule was evaluated with the program APBS,42 and is
shown inFigure 1(b). Themost significant features are
Figure 3. (a) P212121-A 1.9 Å Fo–Fc electron density, contoured at the +3.0 σ level, computed before any modelling of
the ligandwas attempted. The finalmodel for the ricinoleic acid ligand is shownwithC (orange) andO(red) surrounded by
the OmCI pocket residues (C, green; O, red; N, blue; and S, yellow); the picture was produced with PyMol [http://www.
pymol.sourceforge.net/]. (b) A representation of the water molecules and OmCI residues forming hydrogen bonds (with
distances in Å) and non-bonding hydrophobic contacts to the ricinoleic acid. The picture was produced with the program
LigPLot.57
788 Structure of the Tick Complement Inhibitor OmCIa positively charged patch at the brim of the fatty-
acid-binding pocket, which is mainly due to residue
K65; and negative patches on the opposite face of the
molecule, localised on the 310 helix turn and its sur-
roundings, and on the side of the barrel, on helix α3.
Structural similarity to C8γ and C5-C345C domain
While the closest OmCI structural homologues are
tick proteins, the protein also bears intriguing
structural similarity to two complement protein
domains, namely C8γ and the C345C domain of
complement proteins C3, C4 and C5.
C8γ is a 22 kDa domain of complement component
C8. Although C8γ is not essential for complement-
mediated lysis, C8 lacking this domain shows
impaired activity.43 C8γ has a lipocalin fold,44 and
its overall size and shape, as well as its hydropho-
bic pocket, are very similar to those of OmCI (2.8 Å
rmsd over 91 Cα atoms). Although physiological
ligands have yet to be identified, both OmCI and
C8γ are likely to bind fatty acids or related com-
pounds. As was hypothesised for C8γ,44 OmCI may
bind inflammatory response mediators or modula-
tors; these molecules are likely to be produced at the
site of complement activation during tick feeding,
and by sequestering them via OmCI, the tick would
interfere with the host inflammatory response.
The other complement protein domain that OmCI
shows structural similarity to is the C345C domainof complement components C3, C4 and C5. This
domain is involved in interactions between terminal
components of complement; in particular, it has
been shown to be essential for C5 cleavage by the C5
convertases and for C5 activation.29 When super-
imposing OmCI onto the NMR structure of the
C345C domain of C5, PDB ID 1XWE, five β strands
of OmCI (BCDAH) align with five β strands of C5
C345C (ABCDE2),26 with rmsd of 2.0 Å over 44 Cα
atoms. In this superposition, the DE loop of the C5
C345C domain that is necessary for C5 cleavage and
activation is overlaid by the OmCI EF loop, one of
the sites of sequence difference between OmCI and
its sequence homologues (see Figure 2).29
A model for the interaction of OmCI with C5
On the basis of the C5 C345C and OmCI structural
similarity,we propose amechanism for the C5:OmCI
complex that involves OmCI displacing the C5
C345C domain from the surface of C5. For this
model to be correct, the linker between the C5 C345C
domain and the rest of the C5 molecule needs to be
flexible enough to allow the displacement of the
C345C domain by the OmCI molecule. This is
supported by a number of observations based on
the structures of the C5 homologues C3 and C3b: (i)
the contact area of the C3 C345C domain with the
rest of themolecule in the C3 structure is only 960 Å2,
with an estimated energy for the interaction of less
789Structure of the Tick Complement Inhibitor OmCIthan 5 kcal/mol;45 (ii) the relative orientation of the
C3 C345C domain with respect to the main body of
themolecule shows a large degree of flexibility when
comparing the structure of C3 with those of C3b
(PDB ID 2I07) andC3b:CRIg complex (PDB ID 2ICF):
in the C3b structure the C3 C345C domain is swung
out by 22° and moves by about 20 Å away from the
position it occupies in C3; in the C3b:CRIg complex,
the rotation is about 35° and the shift about 37 Å
away from the C3 position; (iii) the anchor regionFigure 4. (a) A model for the region of C5 around its C-ter
structure of the C5 C345C domain (coloured cyan, from PD
homology model for the neighbouring surface of the C5 molecu
C3, PDB ID 2A73. The contact areas of this homology model
light blue. The C5 C345C DE loop critical for the interaction w
red. (b) The proposed model for the complex between OmCI
(green), superposed on the NMRmodel of the C5 C345C place
C5 surface (without the C345C domain) is coloured as in (a). T
representation of the two chain structure of C5, modelled aft
bond linking the C5α and C5 α chains, and the one linking th
symbolised by black lines. The N-terminal domain of the C5 α
C-terminal domain of the C5α chain (the C345C domain) is co
coloured red; the rest of the C5 α chain is coloured blue. The C5
cleavage of the C5α chain occurs are coloured black and ar
crosslinking mixtures (see Materials and Methods). Left-hand s
hand side lanes: Immunoblot with anti-OmCI antibodies. Lan
C5; lanes 2 and 5, crosslinking in the presence of C5 only; lane
upward shift in C5α, but not C5α, in the presence of OmCI (lan
and (c) were produced with the program PyMol [http://www(residues 1475–1495) securing the C3 C345C domain
to the main body of C3 undergoes large conforma-
tional changes upon going from C3 to C3b.21–23
To further refine our hypothesis, we first gener-
ated a homology model for the C5 structure, based
on the structure of C3 (28.2% identity and 48.3%
similarity); and then incorporated the NMR struc-
ture of the C5 C345C domain in this model by sub-
stituting it for the same domain of the C5 homology
model (see Figure 4(a)). In this C5 model, the DEminal C345C domain. In cartoon representation, the NMR
B ID 1XWE). In surface representation, coloured blue, a
le (excluding the C345C domain) based on the structure of
for the rest of C5 with the C5 C345C domain are coloured
ith the C5-convertase (C5 residues 1622–1640) is coloured
and C5. In cartoon representation, the structure of OmCI
d as described above (see (a)). The homology model for the
he OmCI loops BC, DE and EF are coloured orange. (c) A
er the C3 crystal structure, PDB ID 2A73. The disulphide
e C345C domain to the main body of the C5 α chain, are
chain (the C5 anaphylotoxin, (C5a)) is coloured orange; the
loured cyan; the DE loop of the C345C domain (see (a)) is
β chain is coloured yellow. Residues R751–L752 where the
e indicated by the arrow. (d) SDS-PAGE gels of the BS3
ide lanes: gel stained with Coomassie brilliant blue. Right-
es 1 and 4, crosslinking in the presence of both OmCI and
s 3 and 6, crosslinking in the presence of OmCI only. The
es 1 and 4), indicates crosslinking of OmCI to C5α. (a), (b)
.pymol.sourceforge.net/].
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cleavage and activation is one of the three contact
points orienting this domain with respect to the rest
of C5.29 The contact area of the C5 C345C domain
with the rest of the C5 molecule in this model for C5
is 880 Å2.
Once this model for C5 was obtained, we built a
model for the interaction of OmCI with the main
body of C5 by overlaying the OmCI crystal structure
on the C5 C345C domain placed as above, and
displacing the C5 C345C domain (see Figure 4(b)).
Both of the main sequence insertions by which
OmCI differs from its closest homologues, located at
the N terminus and at loop GH (see Figure 2), are in
proximity of the main body of C5 in this orientation.
The other two OmCI loops that are in close contact
with the surface of C5 in this model are OmCI loops
BC and DE. The contact area of OmCI with the rest
of the C5 molecule in this model is 1080 Å2, slightly
larger than that computed for the C5 C345C domain
and the main body of C5.
In summary, we hypothesise that (i) the C345C
domain of C5 is in similar placement with respect to
the main body of the molecule to the C345C domain
of C3; and that (ii) the structural similarity of OmCI
to the C5 C345C domain is of functional significance.
On the basis of these hypotheses, we propose that
OmCI inhibits C5 cleavage by dislodging the C5
C345C domain from the position needed for the C5
convertase to approach and/or cleave. This model
for the C5:OmCI interaction implies that several
lysine residues in OmCI would lie close enough to
lysine residues in C5α to allow crosslinking with bis
(sulfosuccinimidyl)suberate (BS3) (cross-linking dis-
tance 12 Å). This prediction is consistent with the
results of our BS3 crosslinking experiments, which
show a mobility-shift of the C5α but not the C5β
chain and, therefore, indicate binding of OmCI to
C5α and not to C5β (see Figure 4(d)).Discussion
When OmCI isolated from the tick saliva was
analysed by GS-MS, no detectable trace of small-
molecule ligands bound to it are found: this suggests
that the presence of a ligand in the pocket is not
critical for folding nor stabilisation of the folded
protein. On the other hand, ricinoleic acid interacts
rather specifically with residues H119 and D121
(with the OH group) and R107 (with the C9=C10
double bond). Given the good complementarity
between ricinoleic acid and the central pocket, it is
likely that any physiological ligand(s) of OmCI will
be lipid or lipid derivatives bearing some similarity
to ricinoleic acid (e.g. a negatively charged head
group, an unsaturation at C9=C10 and a hydrogen
bond donor at position 12). Assuming OmCI
acquires its natural ligand(s) from the host plasma
during the tick's blood meal, derivatives of arachi-
donic acid such as leukotrienes, prostaglandins and
thromboxanes are possible, physiologically relevant
OmCI ligands. By sequestering such molecules,OmCI may further reduce inflammation at the
feeding site. Until the exact identity of the OmCI
ligand(s) in vivo and their role in the interaction
between the tick parasite and the host are eluci-
dated, OmCI remains an orphan lipocalin.
OmCI's tick lipocalin sequence homologues (see
Figure 2), TSGP 2 and TSGP 3 have no putative
function as yet, while moubatin is reported to be a
platelet aggregation inhibitor. The most significant
sequence differences in the residues lining the pocket
between moubatin and OmCI are the substitution of
Leu for Phe at residue 33 and Gly for Arg at residue
107, both ofwhich render the surface of themoubatin
pocket larger (by an estimated 100 Å2). On the basis
of our OmCI structure, we propose that in moubatin
the pocket may be large enough to bind prostanoids
(prostaglandins and thromboxanes) involved in
platelet aggregation.46
The structural similarity of OmCI to the C5 C345C
domain leads to the hypothesis that OmCI inihibits
C5 cleavage by dislodging the same domain from the
surface of C5, thereby disturbing the approach of the
C5 convertase. This model is consistent with the
published evidence that the DE loop of the C5 C345C
domain is necessary for C5 cleavage and acti-
vation,29 and with the results of our crosslinking ex-
periments that demonstrate OmCI binds to the C5α
chain. This model lends support to the hypothesis
that OmCI acts by preventing interactionwith the C5
convertase, rather than by blocking the C5a cleavage
site.13 Further biochemical and structural character-
isation of the C5:OmCI interaction are in progress.
Materials and Methods
Mutation of the glycosylation sites, cloning into
pMETαC, an expression and purification from
Pichia methanolica
Native, mature, OmCI is not glycosylated but its re-
combinant version expressed in P. methanolica is hyper-
glycosylated.13 The asparagine residues of the NX(S/T)
glycosylation sites (N78 and N102) were therefore mu-
tated into glutamine, and expressed in P. methanolica and
purified as described.35 In the following, we refer to this
double mutant N78Q/N102Q Pichia-expressed protein as
pOmCI.
Crystallization and X-ray diffraction
All crystals were grown by the vapour-diffusion,
sitting-drop method at 20 °C; screens were set up using
a crystallisation robot (TECAN, UK). The crystallisation
drops were obtained by mixing 0.2 μl of protein solution
with 0.2 μl of the crystallisation screen, and were equi-
librated against 100 μl of mother liquor. pOmCI crystals
grew by mixing the protein solution at 25.6 mg/ml with
either MD Structure Screen I condition 2 (30% (w/v) PEG
4000, 0.1 M sodium acetate (pH 4.6), 0.2 M ammonium
acetate) or MD Screen I condition 14 (30% PEG 8000, 0.1 M
sodium cacodylate (pH 6.5), 0.2 M ammonium sulphate)
(Molecular Dimensions Structure, USA). The crystals took
over a month to grow to dimensions of approximately
200 μm×80 μm×50 μm.
Table 2. OmCI crystal structure refinements statistics
Crystal P212121-A P212121-B
Resolution range 40.9–1.9 (2.0–1.9) 20–2.3 (2.4–2.3)
Rall (%) 17.1 (17.5) 19.7 (21.2)
Rwork (%) 16.9 (17.3) 19.5 (21.1)
Rfree (%) 21.0 (22.9) 23.4 (22.7)
rmsd from ideal
Bond lengths (Å) 0.014 0.003
Bond angles (deg.) 0.8 0.6
Residues modelled (range) 145 (24–168) 146 (23–168)
Water molecules modelled 160 44
Non-protein molecules One acetate ion;
one ricinoleic acid
One acetate ion;
one ricinoleic acid
Average B values
Protein (Å2) 19.9 19.8
Ligands (Å2) 29.5 30.0
Water molecules (Å2) 33.0 19.2
Ramachandran plot
Residues in favoured
regions (%)
98.6 97.2
Residues in forbidden
regions (%)
0.0 0.0
PDB identifier 2CM4 2CM9
Values for the highest resolution shell are given in parentheses.
791Structure of the Tick Complement Inhibitor OmCIDiffraction data from the pOmCI crystals were collected
at 100K onbeamline ID14-4 at the ESRF (see Table 1 for data
collection statistics). The crystals were cryoprotected with
15% (v/v) glycerol in mother liquor. The crystals belong to
space group P212121, with two slightly different sets of cell
dimensions (P212121-A and P212121-B). Crystals of either
kind grew in the same conditions and could be harvested
from the same drop. All X-ray data integration and scaling
were done using the computer programs Mosflm47 and
Scala.48
Structure determination,model building and refinement
Initial structure factor phases were obtained for the
pOmCI crystals by molecular replacement, with the
female-specific tick histamine-binding protein (PDB ID
1QFT, 21% sequence identity14) as a search model, against
the P212121-A data; the computer program AMoRe49 was
run via the molecular replacement web server CASPR.50
Iterative model building and refinement with programs
xfit51 and Buster-TNT52 completed the structure. An initial
model for the bound fatty acid was built in the residual
electron density, and its exact chemical nature adjusted to
that of ricinoleic acid once the mass-spectroscopy result
was available. Once complete, the P212121-A pOmCI
model was rebuilt and refined against the P212121-B
data, after an initial round of rigid-body refinement, again
using xfit and Buster-TNT. Table 2 contains the final
crystallographic refinement data and statistics.
Isolation and GC-MS analysis of ricinoleic acid from
the recombinant pOmCI
Purified pOmCI in PBS (200 μl; 8.6 mg/ml) was
extracted with CHCl3 (130 μl; 1:1, v/v) and evaporated
to dryness at room temperature with a gentle stream of
nitrogen. A few drops of 6 M diazomethane in ether were
added to methylate the free acid. After 10 min, the solvent
and excess diazomethane were removed by a stream of
nitrogen and the sample was taken up in 10 μl of
dichloromethane. The sample was used directly for gas
chromatography-mass spectrometry (GC-MS) analysis.
The reference ricinoleic acid was likewise methylated by
diazomethane before GC-MS analysis.
Mass spectrometric analysis of ricinoleic acid was
performed on a TraceMS (ThermoFinnigan, D-63329Table 1. OmCI X-ray data collection and processing
Data set P212121-A P212121-B
X-ray source ESRF ID14-4 ESRF ID14-4
Detector ADSC Scanner ADSC Scanner
Space group (Z) P212121 (4) P212121 (4)
Unit cell parameters
a (Å) 45.17 45.09
b (Å) 55.52 54.00
c (Å) 60.62 55.03
α (deg.) 90.0 90.0
β (deg.) 90.0 90.0
γ (deg.) 90.0 90.0
Wavelength (Å) 0.9757 0.9792
Resolution limits (Å) 40.9–1.9 (2.0–1.9) 38.5–2.3 (2.4–2.3)
Completeness (%) 99.6 (99.3) 99.7 (99.7)
Measured reflections 110,764 58,577
Unique reflections 12,509 6331
Multiplicity 8.9 (9.1) 9.2 (7.9)
Rmerge 0.095 (0.371) 0.124 (0.362)
I/σ(I) 6.5 (1.6) 4.8 (1.8)
Values for the highest resolution shell are given in parentheses.Egelsbach, Germany) equipped with fused silica Alltech
EC5 (D-82008 Unterhaching, Germany) capillary column
(15 m×0.25 mm; 0.25 μm film thickness) using He at 1.5 ml
min−1 as the carrier gas. Samples (1 μl) were injected in the
split-less mode (1 min) and separated under programmed
conditions starting at 60 °C (1 min) followed by heating at
10 deg.C min−1 to 180 °C, and at 4 deg.C min−1 to 280 °C
and held there for 2 min. Full scan spectra were measured
in electron impact (EI) mode at 70 eV, with a source
temperature of 200 °C, transfer line at 280 °C, and an
emission current of 250 μA. The instrument was operated
between m/z 30 and m/z 570 at 2 scans s−1.
C5 and C5:OmCI modelling
A homology model for human C5 (1681 residues) was
built with the program Modeller,53 using the crystal
structure of human C3 (1653 residues, PDB ID 2A73) as a
template. The overall level of identity between the
sequences of the two molecules is 28.2%, the overall
similarity is 48.3%. The NMR model of the C5 C345C
domain (PDB ID 1XWE) was superimposed onto the C5
C345C domain of the C5 homology model using the
program LSQMAN,54 the same program was used to
overlay the OmCI crystal structure onto the C5 C345C
domain. The contact areas between the C5 C345C domain
and OmCI with the rest of C5 in these models were
evaluated with the EBI PISA server.45
Crosslinking
Human C5 was purchased from Calbiochem. The C5–
OmCI complex was prepared by adding 2.5 μg of pOmCI
to 5 μg (1 μg/μl) of C5 (approximately fivefold molar
excess of pOmCI), both dissolved in PBS, final volume
9.5 μl. The reaction mixture was incubated at room
temperature for 15 min to allow the complex to form,
before adding the cross-linker bis(sulfosuccinimidyl)sube-
rate (BS3; Pierce) to a final concentration of 0.8 mM. For C5
crosslinking, BS3 was added to 5 μg of C5 in 9.5 μl of PBS;
for OmCI crosslinking, BS3 was added to 2.5 μg of OmCI.
After incubation for30 min, reducing SDS sample buffer
792 Structure of the Tick Complement Inhibitor OmCIwas added. The reduced samples were electrophoresed on
Novex Tris-Tricine gradient 4%–14% (w/v) polyacryla-
mide gels and stained with Coomassie brilliant blue or
transferred to nitrocellulose and immunoblotted with
(1:500, v/v) anti-OmCI polyclonal rabbit serum (a kind
gift from Professor Paul Morgan, Cardiff University
College Hospital, Wales, UK).Acknowledgements
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